回复 ysphappy 的帖子
恩替卡韦+干扰素已经尝试过。你可以在看这份研究报告摘要:
http://www.hbvhbv.com/forum/thread-1094966-1-1.html
另一项研究比较了218 HBeAg阳性患者,他们只是对患者接受恩替卡韦和干扰素不同序列的聚乙二醇干扰素。该集团随后治疗结束后6个月。在后续的结束:
干扰素组HBeAg血清转换率为30.6%,高于24.7%和26%的利率计分由两组顺序干扰素和恩替卡韦治疗。然而,失去了乙肝表面抗原,干扰素组的2.4%至6.8%的速度在接受干扰素和再恩替卡韦组相比。
1386。一个新的联合方案在持续治疗后HBeAg阳性慢性乙型肝炎(CHB)的HBsAg清除的聚乙二醇干扰素α- 2a和恩替卡韦结果。 "Another study compared 218 HBeAg-positive patients who received just pegylated interferon against patients who received varying sequences of entecavir and interferon. The groups were then followed for six months after treatment ended. At the end of the follow-up: The interferon-only group had a HBeAg seroconversion rate of 30.6%, higher than the 24.7% and 26% rates scored by the two groups that did sequential interferon and entecavir treatment. However, 2.4% of the interferon group lost HBsAg, compared to 6.8% rate in the group receiving interferon and then entecavir. 1386. A novel combination regimen of peginterferon alfa-2a and entecavir results in sustained post-treatment HBsAg clearance in HBeAg-positive chronic hepatitis B (CHB). "
|